[Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].

Qiu, A F; Miao, Z L; Ge, G K; Wang, C B; Bian, J; Ma, H Y; Xu, Q

Qiu, A F; Miao, Z L; Ge, G K; Wang, C B; Bian, J; Ma, H Y; Xu, Q.

Affiliation

Qiu AF; Department of General Surgery, the Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng 224001, China.

Zhonghua Yi Xue Za Zhi ; 97(44): 3466-3470, 2017 Nov 28.

Article in Zh | MEDLINE | ID: mdl-29275580

Subject(s)

Anthracyclines/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Neoadjuvant Therapy; Taxoids/therapeutic use; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Prognosis

Key words

Breast neoplasms; Dose-dense; Neoadjuvant chemotherapy; Sequential therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Anthracyclines / Neoadjuvant Therapy / Taxoids Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: Zh Journal: Zhonghua Yi Xue Za Zhi Year: 2017 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google